Menopause History of Treatment Over Decades

The Pre-Pharmaceutical Era: How Menopause Was Understood Before 1940

Before mid-century medicine, menopause was largely a social and psychiatric diagnosis. Physicians attributed hot flashes, irritability, and fatigue to "nervous exhaustion" or "involutional melancholia," and treatment ranged from cold baths to sedatives such as phenobarbital. The ovarian origin of symptoms was suspected as early as 1896 when French physiologist Charles-Edouard Brown-Séquard described organotherapy using glandular extracts, but reproducible formulations did not exist.

Early Endocrine Science Sets the Stage

The isolation of estrone by Edward Doisy and Adolf Butenandt in 1929 changed the conversation. By 1932, researchers had connected ovarian estrogen loss to vasomotor symptoms in a series of clinical observations published in academic endocrinology journals. That decade of basic science made pharmaceutical estrogen a logical clinical target.

Diethylstilbestrol and the First Synthetic Estrogen

Diethylstilbestrol (DES), synthesized in 1938, was the first orally active estrogen. DES was used off-label for menopausal complaints in the early 1940s before its approval for other indications. Its later association with clear-cell adenocarcinoma in daughters of women given DES during pregnancy (documented in a landmark 1971 New England Journal of Medicine report) would shape regulatory caution about estrogenic agents for the next half-century [1].

The Premarin Era: 1942 to the 1970s

Conjugated equine estrogen (CEE), marketed as Premarin by Ayerst Laboratories, received FDA approval in 1942 for menopausal symptoms. Derived from the urine of pregnant mares, it contained a mixture of estrone sulfate, equilin sulfate, and equilenin. Prescribing was modest through the 1940s and 1950s, confined largely to severe vasomotor symptoms in surgical menopause.

Robert Wilson and "Feminine Forever"

The 1966 publication of Robert Wilson's book "Feminine Forever" transformed public perception. Wilson argued that menopause was an estrogen-deficiency disease and that long-term estrogen use could preserve femininity and prevent aging. Prescriptions surged. By the early 1970s, Premarin was among the five most prescribed drugs in the United States.

The Endometrial Cancer Signal: 1975

Enthusiasm cooled sharply in December 1975 when the New England Journal of Medicine published two back-to-back studies showing that unopposed estrogen increased endometrial cancer risk by a factor of four to eight [2]. Premarin prescriptions fell by roughly 40% between 1975 and 1980. The field did not collapse, however. Gynecologists responded by adding progestin to protect the endometrium in women with an intact uterus, creating what we now call combined estrogen-progestogen therapy (EPT).

Progestin Added, Prescribing Rebounds: 1980 to 2001

The 1980s saw a systematic effort to validate the cardiovascular benefits of estrogen that observational studies had suggested. The Nurses' Health Study, which followed 121,700 women beginning in 1976, reported in 1991 that postmenopausal estrogen use was associated with a 44% lower relative risk of major coronary heart disease compared with never-users [3]. That finding, along with evidence of bone preservation and symptom relief, drove a renewed prescribing wave.

Combination Therapy Becomes Standard

By 1990, the combination of conjugated equine estrogen (0.625 mg daily) and medroxyprogesterone acetate (MPA, 2.5 mg daily or 5 mg cyclically) had become the dominant regimen in the United States. Norethindrone and other progestins were more common in Europe. Guidelines from the American College of Obstetricians and Gynecologists and the American Heart Association in the mid-1990s supported preventive use of HRT for cardiovascular disease, moving therapy well beyond symptom control.

Observational Data vs. Trial Data

The HERS trial (Heart and Estrogen/Progestin Replacement Study), published in JAMA in 1998, was the first large randomized controlled trial of CEE plus MPA in postmenopausal women with established coronary heart disease (N=2,763). It found no reduction in non-fatal myocardial infarction or coronary heart disease death over 4.1 years, and an early increase in cardiovascular events in the first year of use [4]. HERS was a warning shot. The field awaited the larger Women's Health Initiative.

The Women's Health Initiative: 2002 and Its Aftermath

The Women's Health Initiative (WHI) was a National Institutes of Health-funded set of randomized controlled trials enrolling 161,808 postmenopausal women aged 50 to 79 across 40 U.S. Clinical centers. The combined CEE plus MPA arm (N=16,608) was stopped early in July 2002 after a mean of 5.2 years because the data monitoring board found that overall health risks exceeded benefits [5].

What the 2002 Report Actually Showed

The primary findings from the initial WHI publication in JAMA were:

• Breast cancer: hazard ratio 1.26 (nominal 95% CI 1.00 to 1.59) for invasive breast cancer
• Coronary heart disease: hazard ratio 1.29 (95% CI 1.02 to 1.63)
• Stroke: hazard ratio 1.41 (95% CI 1.07 to 1.85)
• Pulmonary embolism: hazard ratio 2.13 (95% CI 1.39 to 3.25)
• Colorectal cancer: hazard ratio 0.63 (95% CI 0.43 to 0.92, a benefit)
• Hip fracture: hazard ratio 0.66 (95% CI 0.45 to 0.98, a benefit)

The global index of risks versus benefits was tilted toward harm. Premarin prescriptions dropped from approximately 22 million in 2001 to under 12 million by 2004.

The Re-Analysis That Changed the Story Again

What the initial 2002 reporting obscured was the age composition of the WHI sample. The mean age of enrolled women was 63, well past the typical menopause transition, and nearly 70% were more than 10 years past their final menstrual period. A 2007 re-analysis by Rossouw et al. In JAMA and subsequent analyses published through 2013 demonstrated that the coronary heart disease hazard ratio in women aged 50 to 59 was 0.93 (95% CI 0.65 to 1.33), meaning no statistically significant increase, compared with 1.71 (95% CI 1.05 to 2.79) in women aged 70 to 79 [6]. This "timing hypothesis" or "window of opportunity" concept reshaped guidelines globally.

The Bioidentical Movement and Compounded Hormones: 2002 to 2015

After 2002, many women and prescribers turned to "bioidentical" hormone preparations, primarily compounded formulations of estradiol, progesterone, and sometimes DHEA or testosterone. The term "bioidentical" refers to hormones with a molecular structure identical to those produced by the human body, particularly 17-beta estradiol and micronized progesterone.

FDA-Approved vs. Compounded Products

FDA-approved bioidentical products include transdermal estradiol patches (Vivelle-Dot, Climara), estradiol gels (EstroGel, Divigel), estradiol vaginal rings, and oral micronized progesterone (Prometrium). Compounded preparations lack the standardized pharmacokinetic testing and sterility oversight of approved products. The FDA has repeatedly noted that compounded hormone preparations are not FDA-approved and carry unverified potency and purity risks [7].

What Data Exist on Micronized Progesterone vs. MPA

The E3N cohort study (N=80,377 French women) found that the combination of transdermal estradiol and micronized progesterone carried a lower breast cancer risk than oral estrogen plus synthetic progestins over 8.1 years of follow-up [8]. This observational finding has influenced European prescribing toward transdermal plus micronized progesterone regimens, and the 2022 British Menopause Society guidelines explicitly prefer transdermal estradiol where systemic therapy is indicated.

The Rehabilitation of Hormone Therapy: 2012 to Present

A series of re-analyses, longer-term follow-up reports, and new randomized data restored confidence in appropriately timed hormone therapy for symptomatic women.

KEEPS and ELITE Trials

The Kronos Early Estrogen Prevention Study (KEEPS, N=727, mean age 52.7 years) randomized recently menopausal women to oral conjugated estrogen, transdermal estradiol, or placebo for four years. Published in 2012, it found no significant difference in carotid intima-media thickness progression between groups [9]. The Early versus Late Intervention Trial with Estradiol (ELITE, N=643) found that oral estradiol 1 mg daily slowed carotid intima-media thickness progression in women within six years of menopause, but not in those more than ten years past menopause [10]. Both trials support the timing hypothesis rather than contradict HRT.

Current Guideline Positions

The North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement concludes: "For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture." [11]

The Endocrine Society's 2015 clinical practice guideline states that "the risks of hormone therapy are small in absolute terms for healthy women who are younger than 60 years or are within 10 years of menopause onset." [12]

Absolute contraindications to systemic hormone therapy in current guidelines include unexplained vaginal bleeding, active or recent thromboembolic disease, active or recent arterial cardiovascular disease, known or suspected breast cancer, and known endometrial cancer.

Non-Hormonal Treatments: From SSRIs to Fezolinetant

Not every woman is a candidate for hormone therapy. Non-hormonal options have expanded considerably since 2002, and a structured framework for choosing among them helps clinicians and patients manage this space.

Selective Serotonin and Norepinephrine Reuptake Inhibitors

Paroxetine mesylate 7.5 mg (Brisdelle) received FDA approval in June 2013 as the first non-hormonal prescription drug approved specifically for vasomotor symptoms of menopause [13]. Off-label use of venlafaxine 75 mg daily, desvenlafaxine 100 mg daily, and escitalopram 10 to 20 mg daily also shows efficacy in randomized trials, with hot flash frequency reductions of 40 to 65% compared with baseline.

Gabapentin and Clonidine

Gabapentin 300 mg three times daily reduces hot flash frequency by approximately 45% in controlled trials. Clonidine 0.1 mg twice daily shows modest efficacy (roughly 20 to 25% reduction) and is generally considered a second-line option due to side-effect profile including hypotension and dry mouth.

Fezolinetant: A New Mechanism

Fezolinetant (Veozah, Astellas Pharma) is a selective neurokinin 3 receptor antagonist that targets the KNDy (kisspeptin/neurokinin B/dynorphin) neuronal pathway in the hypothalamus, the pathway directly responsible for temperature dysregulation in menopause. The FDA approved fezolinetant 45 mg once daily on May 12, 2023, based on the SKYLIGHT 1 and SKYLIGHT 2 phase 3 trials [14].

In SKYLIGHT 1 (N=527), fezolinetant 45 mg reduced moderate-to-severe hot flash frequency by 60% from baseline at week 12 compared with 45% for placebo (P<0.001). Fezolinetant is contraindicated in women with cirrhosis, severe renal impairment, or those taking CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin.

Genitourinary Syndrome of Menopause: A Long-Overlooked Domain

Genitourinary syndrome of menopause (GSM), formerly called vulvovaginal atrophy, affects an estimated 50 to 84% of postmenopausal women but was largely absent from mainstream menopause discussions before the term GSM was adopted by NAMS and the International Society for the Study of Women's Sexual Health in 2014.

Local Estrogen Products

Low-dose vaginal estrogen (estradiol vaginal tablets 10 mcg, estradiol vaginal cream, conjugated estrogen cream) delivers minimal systemic absorption and remains appropriate even for many breast cancer survivors per NAMS and ASCO guidance. Prasterone (intravaginal DHEA, Intrarosa), FDA-approved in 2016, converts locally to estrogen and androgen and improves dyspareunia without meaningful systemic estrogen rise [15]. Ospemifene (Osphena), a selective estrogen receptor modulator approved in 2013, is an oral option for women unwilling or unable to use vaginal preparations.

The Breast Cancer Survivor Question

The 2020 NAMS position paper on GSM in breast cancer survivors notes that vaginal estrogen at the lowest effective dose may be considered when non-hormonal therapies have failed, after shared decision-making with the oncologist. This remains an area of active research, and blanket prohibition of any estrogen in all breast cancer survivors is not supported by current data.

Testosterone in Menopause: An Emerging Evidence Base

No testosterone product is currently FDA-approved specifically for postmenopausal women in the United States, yet off-label prescribing of low-dose transdermal testosterone (typically 0.5 to 1 mg daily via gel or cream) for hypoactive sexual desire disorder has grown substantially. The 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women, published in the Journal of Clinical Endocrinology and Metabolism and co-authored by the Endocrine Society, NAMS, British Menopause Society, and other major bodies, concluded that there is Level 1 evidence supporting testosterone use for hypoactive sexual desire disorder in postmenopausal women [16]. Target serum total testosterone levels are the upper end of the premenopausal physiologic range, roughly 15 to 70 ng/dL.

A Decade-by-Decade Summary

| Decade | Key Development | Net Clinical Direction | |---|---|---| | 1940s | Premarin approved (1942) | Estrogen for surgical menopause | | 1960s | "Feminine Forever" (1966) | Mass prescribing begins | | 1970s | Endometrial cancer signal (1975) | Progestin added; prescribing cautious | | 1980s | Nurses' Health Study cardiovascular data | Preventive HRT narrative grows | | 1990s | HERS trial (1998) challenges cardiac benefit | Uncertainty increases | | 2000s | WHI publication (2002) | Major prescribing collapse; bioidentical surge | | 2010s | Timing hypothesis; KEEPS, ELITE | Selective rehabilitation of HRT | | 2020s | Fezolinetant approved (2023); testosterone consensus | Expanded non-hormonal and androgen options |

What the Current Evidence Supports: A Practical Clinical Summary

For a healthy woman aged 45 to 59 with bothersome vasomotor symptoms and no contraindications, individualized hormone therapy remains the most effective treatment available. The NAMS 2022 position statement assigns the highest efficacy rating to systemic estrogen for hot flashes, with or without progestogen depending on uterine status [11].

Women who cannot use systemic estrogen (active breast cancer, prior thromboembolic event, uncontrolled hypertension) have evidence-based alternatives: fezolinetant 45 mg daily for vasomotor symptoms, local vaginal estrogen or prasterone for GSM, and SSNRIs or gabapentin for moderate hot flash relief. Cognitive behavioral therapy for menopause (CBT-M) has also shown a statistically significant reduction in problem rating of hot flashes in the MENOS 1 trial (N=96) [17].

The absolute risk numbers from the WHI, properly contextualized, show that for women aged 50 to 59 taking combined CEE plus MPA for five years, the estimated excess risk of breast cancer is approximately 8 additional cases per 10,000 woman-years. That figure must be weighed against quality of life, bone density preservation, and the now-established reduction in all-cause mortality seen in the estrogen-alone arm of WHI among younger initiators.

Per the NAMS 2022 guideline: "Duration of use should not be arbitrarily restricted for women aged younger than 60 years who have bothersome symptoms and understand the benefit-risk ratio." Current prescribing data from 2023 indicate roughly 4.7 million U.S. Women are receiving some form of menopausal hormone therapy, well below the 2001 peak but rising again as the timing hypothesis becomes more widely applied in clinical practice.